A Phase 1 Study of PBCAR19B in Subjects with CD19-expressing Malignancies
|Precision BioSciences, Inc.
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / email@example.com
The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR19B to treat certain types of cancers. PBCAR19B is a new investigational treatment for certain types of cancer of the blood, such as leukemia and lymphoma. It is made from a type of blood cells known as T cells. The T cells in PBCAR19B came from healthy people who have donated their blood. The donated T cells have been genetically changed, so that they may be able to kill some types of cancer cells.
This study is closed
Ran Reshef, MD
|Are you age 18 or older?
|Do you have lymphoma that has come back or not responded to treatment?
|Are you able and willing to provide written informed consent?